Our study demonstrates oxygenation immediately after the CO2 facial is more significant than exfoliation alone…Our data provides evidence for the ability of the CO2 facial to oxygenate tissue immediately after treatment.
Tel Aviv, Israel (PRWEB) September 10, 2015
Pollogen Ltd., a global leader in the development of medical devices for the aesthetics market, announced the publication of a new peer-reviewed article proving the effectiveness of OxyGeneo CO2 facial treatments. The clinical results showed that oxygenation immediately after an OxyGeneo CO2 facial is more effective than exfoliation alone and that OxyGeneo CO2 facials improve skin oxygenation immediately following treatment. The study “Effect of Carbon Dioxide Facial Therapy on Skin Oxygenation” was recently published in the Journal of Drugs in Dermatology, authored by Ronald Moy, M.D. Moy-Fincher-Chipps Dermatology (Beverly Hills, CA), Rachel Seidel BA, Georgetown University School of Medicine (Washington, DC). The study was performed using the OxyGeneo super facial treatment which is part of the geneO+ platform (Pollogen Ltd., Tel Aviv Israel).
“Our study demonstrates oxygenation immediately after the CO2 facial is more significant than exfoliation alone…Our data provides evidence for the ability of the CO2 facial to oxygenate tissue immediately after treatment.”
This was a split-face study. Twelve patients were treated one week apart with an OxyGeneo CO2 facial on one side of the face and particle-free microdermabrasion on the other. Results showed that the effectiveness of CO2 facial treatments to oxygenate the skin using OxyGeneo were statistically significantly greater than after microdermabrasion (p = .0252).
OxyGeneo super facial is an innovative skin renewal treatment that delivers three essential facial treatments simultaneously as it exfoliates the outer layer of the skin, prepares it for the infusion of revitalizing nutrients and stimulates its oxygenation. OxyGeneo generates the Bohr Effect, an exchange of O2 with CO2 at the level of dermal capillaries, which triggers the body’s response to send oxygen to the treated area. OxyGeneo super facial treatments result in unparalleled skin nourishment & oxygenation, for a smoother complexion and younger looking skin. They improve skin tone and allow for the optimal absorption of revitalizing nutrients. Results are visible after only one treatment and safe for any skin type.
Mr. Moshe Shneor – CEO Pollogen Ltd. “We are thrilled about this new clinical study validating the clinical value of OxyGeneo technology as it offers a gentle yet powerful treatment for skin rejuvenation. OxyGeneo super facials are changing the concept and effectiveness of traditional facial treatments. By creating a single system with three powerful technologies, Pollogen is providing the tools needed for aestheticians to get the best results for their clients.”
Pollogen believes in constantly challenging itself to create the most advanced, effective medical aesthetic technologies and solutions. The Company believes in thinking differently.
Pollogen takes a customer-centric approach by making our products user-friendly, safe and convenient. The Company believes in finding ways to develop technologies that work with the body’s natural mechanisms so beautiful results are generated from within.
Pollogen is the developer and manufacturer of five revolutionary technologies under the industry premier brand names OxyGeneo®, VoluDerm™, Hybrid Energy™, TriPollar®, TriLipo® and TriFractional™. We offer a full line of clinically-proven, safe and effective, non-invasive anti-aging facial and body contouring treatment platforms for a wide range of aesthetic applications. Pollogen provides solutions for professionals in over 60 countries, addressing the specific needs and dynamic changes unique to the ever-evolving aesthetic industry.